Global consumer healthcare company Haleon has announced plans to invest ₹2,500 crore in a new manufacturing facility in Pithampur, Madhya Pradesh, reinforcing its long-term commitment to India, one of the fastest-growing consumer healthcare markets in the world.
The investment marks a significant milestone for the company as it deepens its manufacturing presence in the country and positions India as a key pillar of its future growth strategy. In a further sign of the market’s growing importance, Haleon is also hosting its global board meeting in India for the first time.
India Emerges as a Key Growth Engine
As consumer demand for health, wellness, and self-care products continues to rise, India has become an increasingly important market for multinational healthcare companies.
Haleon CEO Brian McNamara described India as a major growth opportunity for the company, highlighting the country’s strong economic fundamentals, expanding middle class, and increasing focus on preventive healthcare.
The company views India as a strategic market capable of driving long-term business growth while serving as an important manufacturing and export hub for the broader Asia region.
New Facility to Boost Local Manufacturing
The proposed manufacturing plant in Madhya Pradesh represents a major shift in Haleon’s India strategy.
While the company has traditionally relied on third-party manufacturing partners, the new facility will strengthen in-house production capabilities and improve supply chain efficiency.
The plant is expected to focus initially on the production of oral healthcare products, particularly under the Sensodyne brand, one of Haleon’s flagship oral care portfolios.
The facility will cater to growing domestic demand while also supporting exports to key international markets across Asia.
Supporting Ambitious Consumer Reach Targets
Haleon has set an ambitious goal of reaching one billion additional consumers globally by 2030, with India expected to play a crucial role in achieving that objective.
According to Kedar Lele, CEO of Haleon India, the company aims to reach approximately 300 million consumers in India over the coming years as awareness around healthcare, nutrition, and wellness continues to expand.
The new manufacturing facility is expected to become operational by 2029–30 and will serve as a critical component of the company’s long-term expansion plans.
Strengthening India’s Manufacturing Ecosystem
The investment aligns with India’s broader push to attract global manufacturing investments and strengthen domestic production capabilities.
The facility is expected to generate employment opportunities, support local supply chains, and contribute to the development of the country’s healthcare manufacturing ecosystem.
Industry experts believe that increasing local production will help companies respond more efficiently to changing consumer demand while reducing supply chain dependencies.
Building on the Post-GSK Growth Journey
Haleon was established as an independent consumer healthcare company following the merger and restructuring of GSK Consumer Healthcare.
The company owns several well-known health and wellness brands, including Sensodyne, Horlicks, Boost, Panadol, Centrum, and Eno, serving millions of consumers worldwide.
Since becoming an independent business, Haleon has focused on expanding its presence in high-growth markets and strengthening its portfolio across oral health, nutrition, pain relief, digestive health, and vitamins.
India has emerged as one of the company’s most promising markets due to its large consumer base and rapidly evolving healthcare landscape.
Rising Demand Fuels Healthcare Market Growth
India’s consumer healthcare industry is witnessing strong growth driven by:
- Increasing health awareness among consumers
- Rising disposable incomes
- Expansion of preventive healthcare practices
- Growing demand for nutrition and wellness products
- Improved healthcare accessibility
- Rapid urbanization and digital health adoption
These factors are creating significant opportunities for companies operating in the self-care and consumer health segments.
Outlook
Haleon’s ₹2,500 crore investment highlights the growing importance of India in the global consumer healthcare industry.
By establishing a large-scale manufacturing facility in Madhya Pradesh, the company is strengthening its local production capabilities, enhancing export potential, and positioning itself to capture rising demand across the health and wellness sector.
As India’s consumer healthcare market continues to expand, investments of this scale are expected to play a vital role in supporting manufacturing growth, job creation, and innovation while reinforcing the country’s position as a strategic hub for global healthcare companies.
